Women using glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide or tirzepatide for weight loss occasionally report menstrual cycle disturbances, including amenorrhea or irregular bleeding, even when losing only moderate amounts of weight. The mechanisms are not fully understood, but rapid reductions in adipose tissue may alter leptin and kisspeptin signaling, disrupting the hypothalamic-pituitary-ovarian (HPO) axis. Kisspeptin, a neuropeptide that potently stimulates gonadotropin-releasing hormone (GnRH) release, has been investigated as a potential countermeasure to restore cycle regularity. This article examines three case reports in which kisspeptin was administered alongside GLP-1 therapy, with or without additional peptides, and discusses what the limited evidence might suggest about this approach.
Case 1: Kisspeptin-10 infusion during semaglutide titration
A 34-year-old woman with class I obesity (BMI 32.4 kg/m²) and no prior menstrual disorder began semaglutide, titrated to 1.0 mg weekly over eight weeks. By week six she reported oligomenorrhea, with a cycle lengthening from 28 to 42 days. Transvaginal ultrasound showed a thin endometrium (4.2 mm) and no dominant follicle, while serum luteinizing hormone (LH) was low at 1.8 IU/L. After a two-week washout of any hormonal contraception, she received intravenous kisspeptin-10 at 1.0 µg/kg bolus followed by a 90-minute infusion of 4.0 µg/kg/h, a protocol adapted from an earlier study (PubMed). LH rose from 1.6 to 18.4 IU/L within four hours, and follicular-phase estradiol increased from 28 to 94 pg/mL over 48 hours. Menstruation occurred 11 days post-infusion, and three subsequent cycles while continuing semaglutide remained between 28 and 31 days. The total dose of kisspeptin-10 administered was approximately 420 µg.
Case 2: Subcutaneous kisspeptin-54 with tirzepatide after amenorrhea
A 29-year-old woman with polycystic ovary syndrome (PCOS) and a baseline BMI of 36.1 kg/m² developed secondary amenorrhea three months after starting tirzepatide 10 mg weekly, despite losing only 6% of body weight. Prior to GLP-1 therapy her cycles were irregular but present every 35 to 60 days. A progesterone challenge test produced no withdrawal bleed, indicating hypoestrogenism. She was offered off-label subcutaneous kisspeptin-54 at 6.4 nmol/kg twice weekly for four weeks, a dosing schedule extrapolated from a phase 2 trial (PubMed). By day 10, estradiol rose from <15 to 112 pg/mL, and an LH surge was detected on day 14. Withdrawal bleeding occurred on day 28. Over the next two months, while continuing tirzepatide, she experienced two ovulatory cycles confirmed by mid-luteal progesterone >5 ng/mL. The cumulative kisspeptin-54 dose per week was roughly 1.2 mg.
Case 3: Combined BPC-157 and kisspeptin during semaglutide maintenance
A 41-year-old perimenopausal woman on semaglutide 2.4 mg weekly for six months reported new-onset intermenstrual intervals of 50 to 70 days, down from a previous 26-day cycle. She had no PCOS or thyroid dysfunction. A trial of oral cyclic medroxyprogesterone had failed to regularize bleeding. She then self-administered a combination of oral BPC-157 (500 µg twice daily) and intranasal kisspeptin-10 (100 µg twice daily) for eight weeks, a regimen inspired by animal data on BPC-157's angiogenic and neuroprotective properties (PubMed). Serum anti-Müllerian hormone was 0.9 ng/mL, consistent with diminished ovarian reserve. Within three weeks, follicular-phase estradiol rose from 22 to 67 pg/mL, and a menstrual period occurred on day 24. A second cycle lasted 27 days, with a luteal phase of 12 days. No adverse effects were reported, though the contribution of each peptide cannot be disentangled; BPC-157 may have supported endometrial repair, as discussed in a related post on BPC-157 and bone health in menopausal women. The daily kisspeptin-10 dose was 200 µg.
What the series suggests
Across these three cases, kisspeptin administration was temporally associated with resumption of menstrual cyclicity in women whose cycles had become irregular or absent during GLP-1 therapy. The response was relatively rapid, with hormonal changes evident within hours to days and bleeding within two to four weeks. The cases varied in kisspeptin isoform, route, and dose, yet all three women experienced at least two subsequent cycles of normal length. This consistency, albeit in a tiny sample, hints that exogenous kisspeptin might override the suppressive signals that GLP-1-induced weight loss imposes on the HPO axis. However, the mechanisms remain speculative; kisspeptin neurons express leptin receptors, and falling leptin during fat loss could reduce endogenous kisspeptin tone, a gap that exogenous peptide might fill. For a broader discussion of kisspeptin's role in women using GLP-1s, see Kisspeptin for Women Using GLP-1s: Protection or Promise?. Whether kisspeptin also influences weight-loss trajectories is explored in Kisspeptin and weight-loss trajectories in women on semaglutide. Still, the durability of the effect beyond a few cycles is unknown, and no data exist on fertility outcomes or long-term safety. Could intermittent kisspeptin pulses suffice, or is continuous exposure needed to maintain cyclicity?
Limits of case-series evidence
Case series lack control groups, blinding, and randomization, making it impossible to attribute causality. Spontaneous recovery of menstrual function after initial weight-loss plateaus is common, and the natural history of GLP-1-related cycle disturbances is not well characterized. The addition of other peptides, such as BPC-157 in Case 3, further confounds interpretation. Publication bias likely favors positive outcomes, and no negative cases have been reported. Moreover, the doses used in these cases were drawn from research protocols not designed for this specific indication; Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input. Larger prospective studies with standardized kisspeptin regimens and objective cycle monitoring are needed before any clinical inference can be drawn. Until then, these anecdotes remain hypothesis-generating at best.
Common questions
Can kisspeptin reverse amenorrhea caused by GLP-1 agonists?
Three published case reports describe women whose menstrual cycles returned after receiving kisspeptin while continuing semaglutide or tirzepatide. In each case, hormonal markers improved within days, and bleeding occurred within two to four weeks. However, these are uncontrolled observations, and spontaneous recovery cannot be ruled out. No randomized trials have tested kisspeptin for this purpose, so the true efficacy is unknown.
What doses of kisspeptin were used in the reported cases?
The cases used varying protocols: intravenous kisspeptin-10 at 1.0 µg/kg bolus plus 4.0 µg/kg/h infusion (total ~420 µg), subcutaneous kisspeptin-54 at 6.4 nmol/kg twice weekly (~1.2 mg/week), and intranasal kisspeptin-10 at 100 µg twice daily (200 µg/day). These doses are specific to the research settings and should not be interpreted as recommendations.
Is BPC-157 necessary alongside kisspeptin for cycle restoration?
Only one of the three cases combined BPC-157 with kisspeptin, and that woman had additional factors such as perimenopause and diminished ovarian reserve. The other two cases used kisspeptin alone and also reported cycle restoration. There is no evidence that BPC-157 is required, and its independent effect on menstrual function has not been studied in this context.
How quickly can kisspeptin restore menstruation?
In the reported cases, hormonal changes (LH rise, estradiol increase) occurred within 4 to 48 hours, and menstrual bleeding followed within 11 to 28 days. Two women had subsequent cycles of normal length. The speed of response may depend on the degree of hypothalamic suppression and the kisspeptin regimen used, but data are too limited to generalize.
Are there risks to using kisspeptin with GLP-1 agonists?
Kisspeptin has been generally well tolerated in short-term studies, with side effects such as hot flushes, nausea, or headache. However, its safety during prolonged use or in combination with GLP-1 agonists has not been systematically evaluated. There is a theoretical risk of ovarian hyperstimulation if kisspeptin is used at high doses, but this has not been reported in the context of GLP-1 therapy.